Advertisement
Singapore markets closed
  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     
  • S&P 500

    5,003.43
    -68.20 (-1.34%)
     
  • Dow

    37,987.39
    -473.53 (-1.23%)
     
  • Nasdaq

    15,383.34
    -329.41 (-2.10%)
     
  • Bitcoin USD

    62,981.68
    -2,896.89 (-4.40%)
     
  • CMC Crypto 200

    1,342.91
    -39.66 (-2.87%)
     
  • FTSE 100

    8,048.96
    +8.58 (+0.11%)
     
  • Gold

    2,330.00
    -8.40 (-0.36%)
     
  • Crude Oil

    83.03
    +0.22 (+0.27%)
     
  • 10-Yr Bond

    4.7310
    +0.0790 (+1.70%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     
  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Where Will Cassava Sciences Be in 1 Year?

Where Will Cassava Sciences Be in 1 Year?

First, the company produced strong results in clinical studies for its potential therapy for Alzheimer's disease (AD), Simufilam. The other reason is the result of Biogen, a competitor, receiving regulatory approval in the U.S. last year for its novel AD treatment -- the first such therapy approved for AD since 2003.